Related references
Note: Only part of the references are listed.Hepatitis C Virus Subverts Liver-Specific miR-122 to Protect the Viral Genome from Exoribonuclease Xrn2
Cecilia D. Sedano et al.
CELL HOST & MICROBE (2014)
Identification of PTC725, an Orally Bioavailable Small Molecule That Selectively Targets the Hepatitis C Virus NS4B Protein
Zhengxian Gu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Treatment of HCV Infection by Targeting MicroRNA
Harry L. A. Janssen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Unconventional miR-122 binding stabilizes the HCV genome by forming a trimolecular RNA structure
Stefanie A. Mortimer et al.
NUCLEIC ACIDS RESEARCH (2013)
Competing and noncompeting activities of miR-122 and the 5′ exonuclease Xrn1 in regulation of hepatitis C virus replication
You Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Profile of alisporivir and its potential in the treatment of hepatitis C
Philippe A. Gallay et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2013)
New antiviral therapies in the management of HCV infection
Harald Farnik et al.
ANTIVIRAL THERAPY (2012)
Evaluation of ITX 5061, a Scavenger Receptor B1 Antagonist: Resistance Selection and Activity in Combination With Other Hepatitis C Virus Antivirals
Haihong Zhu et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles
Eva van Rooij et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1
Anna S. Lok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Treating hepatitis C infection by targeting the host
Shadi Salloum et al.
TRANSLATIONAL RESEARCH (2012)
miR-34 – a microRNA replacement therapy is headed to the clinic
Andreas G. Bader
Frontiers in Genetics (2012)
Comparative Study of the Genetic Barriers and Pathways towards Resistance of Selective Inhibitors of Hepatitis C Virus Replication
Leen Delang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Mutations in HCV non-structural genes do not contribute to resistance to nitazoxanide in replicon-containing cells
Changsuek Yon et al.
ANTIVIRAL RESEARCH (2011)
New opportunities in anti-hepatitis C virus drug discovery: Targeting NS4B
Roopa Rai et al.
ANTIVIRAL RESEARCH (2011)
New HCV therapies on the horizon
J. Vermehren et al.
CLINICAL MICROBIOLOGY AND INFECTION (2011)
Masking the 5′ terminal nucleotides of the hepatitis C virus genome by an unconventional microRNA-target RNA complex
Erica S. Machlin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
MicroRNA-122 antagonism against hepatitis C virus genotypes 1-6 and reduced efficacy by host RNA insertion or mutations in the HCV 5′ UTR
Yi-Ping Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents
C. A. Stein et al.
NUCLEIC ACIDS RESEARCH (2010)
DEB025 (Alisporivir) Inhibits Hepatitis C Virus Replication by Preventing a Cyclophilin A Induced Cis-Trans Isomerisation in Domain II of NS5A
Lotte Coelmont et al.
PLOS ONE (2010)
Therapeutic Silencing of MicroRNA-122 in Primates with Chronic Hepatitis C Virus Infection
Robert E. Lanford et al.
SCIENCE (2010)
Position-dependent function for a tandem microRNA miR-122-binding site located in the hepatitis C virus RNA genome
Catherine L. Jopling et al.
CELL HOST & MICROBE (2008)
microRNA-122 stimulates translation of hepatitis C virus RNA
Jura Inga Henke et al.
EMBO JOURNAL (2008)
LNA-mediated microRNA silencing in non-human primates
Joacim Elmen et al.
NATURE (2008)
Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system
Yupeng He et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Interferon modulation of cellular microRNAs as an antiviral mechanism
Irene M. Pedersen et al.
NATURE (2007)
Cellular cofactors affecting hepatitis C virus infection and replication
Glenn Randall et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2
Baofeng Yang et al.
NATURE MEDICINE (2007)
Suppression of microRNA-silencing pathway by HIV-1 during virus replication
Robinson Triboulet et al.
SCIENCE (2007)
Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry
Mike Westby et al.
JOURNAL OF VIROLOGY (2007)
Oncomirs - microRNAs with a role in cancer
A Esquela-Kerscher et al.
NATURE REVIEWS CANCER (2006)
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
C Esau et al.
CELL METABOLISM (2006)
Silencing of microRNAs in vivo with 'antagomirs'
J Krützfeldt et al.
NATURE (2005)
Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA
CL Jopling et al.
SCIENCE (2005)
A microRNA polycistron as a potential human oncogene
L He et al.
NATURE (2005)
MicroRNA expression profiles classify human cancers
J Lu et al.
NATURE (2005)
Global epidemiology of hepatitis C virus infection
CW Shepard et al.
LANCET INFECTIOUS DISEASES (2005)
In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061 - Structural analysis indicates different resistance mechanisms
C Lin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Viral and cellular determinants of hepatitis C virus RNA replication in cell culture
V Lohmann et al.
JOURNAL OF VIROLOGY (2003)
Share Paper
